Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The present project is a multicenter, phase II trial which aims at evaluating if the
administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could
improve the response rate to DLI in the population of patients with relapsed acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell
transplantation.